skinny.

Latest / Breastcancer.org Podcast

Experimental Capivasertib Seems Promising for Advanced-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer

Researchers are always looking for new treatments for advanced-stage breast cancer. Dr. Nicholas Turner explains the results of the CAPitello-291 trial, looking capivasertib, an experimental targeted therapy medicine, in combination with Faslodex (chemical name: fulvestrant) as a treatment for advanced-stage, hormone receptor-positive, HER2-negative breast cancer that has become resistant to the aromatase inhibitors.

Listen to the episode to hear Dr. Turner explain:

how capivasertib works

the results of the CAPitello-291 trial

how capivasertib worked on cancers previously treated with a…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.